- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01265602
Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis
July 23, 2012 updated by: Almirall, S.A.
The aim of this study is to determine the efficacy, safety and tolerability of LAS41007 compared to a marketed reference product as well as to vehicle (topical application, twice daily, indication mild to moderate AK).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
889
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Vechta, Germany, 49377
- Almirall Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have at least 6 but not more than 16 clinically confirmed AK target lesions of mild to moderate (grade I to II, according to Olsen et al., 1991) intensity in the whole treatment area (TA) (and additionally one representative AK lesion for histological diagnosis of AK), which must be located in the face including the forehead (excluding eyelids, lips and mucosa) and/or bald scalp,
- The AK target lesions must be discrete and quantifiable; the distance from one lesion to its neighbor lesion must be greater than 1.0 cm,
- The diameter of each AK target lesion should be not less than 0.5 cm and not greater than 1.5 cm,
- The target lesions must be located in up to 3 TAs with a size of 25 cm2 per TA (i.e. total area of TA is up to 75 cm2),
- Diagnosis of AK histologically confirmed
Exclusion Criteria:
- Have known hypersensitivity, intolerance or allergies against ingredients of the IMPs and other non-steroidal anti-inflammatory agents,
- Have a history of bronchospasm, asthma, urticaria, or rhinitis after the intake of non-steroidal anti-inflammatory drugs (NSAIDs),
- Have a history of gastrointestinal bleeding or perforation associated with prior therapy with NSAIDs,
- Have evidence of clinically significant or unstable medical conditions,
- Have currently and within the past 3 months other malignant tumors of the skin in the TAs,
- Suffer from paresthesia in the TAs,
- Show cornu cutaneum of the skin and/or hypertrophic AK lesions in the TAs,
- Are known to be pregnant or lactating (currently or within the past 3 months),
- Any clinically relevant abnormal finding during Screening and/or Baseline,
- Specific topical treatments in the target area within defined time periods.
- Specific physical treatments in the TAs within defined time periods.
- Specific systemic treatments within defined time periods.
- Patients suffering from AK in locations other than the target areas, receiving any topical AK-therapy throughout the interventional phase of the study until termination of V6,
- Patients who need a permanent therapy with any other NSAID. The use of NSAIDs as "prn" (pro re nata), i.e. to be taken as needed (≤ 3 days at a stretch) and the use of ASA as anticoagulative therapy will be allowed,
- Patients taking methotrexate or sulfonylurea during the interventional phase of the study,
- Anticoagulative therapy, e.g. with cumarines or heparines throughout the interventional phase of the study. Treatment with ASA at a dose not exceeding 100 mg/d and clopidogrel at a dose not exceeding 75 mg/d will be allowed,
- Patients having any significant physical abnormalities in the potential TAs that may cause difficulty with examination or final evaluation,
- Have any dermatological disease in the TAs or surrounding area that may be exacerbated by treatment with topical diclofenac or cause difficulty with examination,
- Physical or mental inability and/or unwillingness to apply the study preparations correctly and to follow the study restrictions and visits,
- Any suspicion of current drug and/or alcohol abuse as assessed by the investigator,
- Anticipated non-availability for study visits / procedures,
- Exposure to an investigational product within the last 3 months,
- Any previous randomization into this trial,
- Patient is institutionalized because of legal or regulatory order,
- Employee of the study site or of the Sponsor's company or the CRO.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LAS41007
All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening.
Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum.
The IMPs will be applied for 90 days in maximum.
|
Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days.
Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
|
Active Comparator: LASW1510
All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening.
Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum.
The IMPs will be applied for 90 days in maximum.
|
Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days.
Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
|
Placebo Comparator: vehicle
All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening.
Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum.
The IMPs will be applied for 90 days in maximum.
|
Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days.
Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
superiority of LAS41007 compared to vehicle
Time Frame: Day 1
|
superiority of LAS41007 compared to comparator each assessed by histology to evaluate the histological clearance of one pre-selected target lesion
|
Day 1
|
superiority of LAS41007 compared to vehicle
Time Frame: Day 150
|
superiority of LAS41007 compared to comparator each assessed by histology to evaluate the histological clearance of one pre-selected target lesion
|
Day 150
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
superiority of LAS41007 compared to vehicle
Time Frame: Day 1
|
improved clinical efficacy of LAS41007 compared to comparator with respect to clinical efficacy
|
Day 1
|
superiority of LAS41007 compared to vehicle
Time Frame: Day 21
|
improved clinical efficacy of LAS41007 compared to comparator with respect to clinical efficacy
|
Day 21
|
superiority of LAS41007 compared to vehicle
Time Frame: Day 56
|
improved clinical efficacy of LAS41007 compared to comparator with respect to clinical efficacy
|
Day 56
|
superiority of LAS41007 compared to vehicle
Time Frame: Day 90
|
improved clinical efficacy of LAS41007 compared to comparator with respect to clinical efficacy
|
Day 90
|
superiority of LAS41007 compared to vehicle
Time Frame: Day 150
|
improved clinical efficacy of LAS41007 compared to comparator with respect to clinical efficacy
|
Day 150
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Dr. Estrella Estrella Garcia, PhD, Almirall, S.A.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Primary Completion (Actual)
March 1, 2012
Study Completion (Actual)
March 1, 2012
Study Registration Dates
First Submitted
December 21, 2010
First Submitted That Met QC Criteria
December 22, 2010
First Posted (Estimate)
December 23, 2010
Study Record Updates
Last Update Posted (Estimate)
July 24, 2012
Last Update Submitted That Met QC Criteria
July 23, 2012
Last Verified
July 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H 569 000 - 1004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Actinic Keratosis
-
Dolorgiet GmbH & Co. KGd.s.h. statistical services GmbH; CenTrial GmbHCompletedActinic Keratosis Olsen Grade I/IIGermany
-
Cosmetique Active InternationalNot yet recruiting
-
Centre Dermatologique du RoyCompleted
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
University of California, DavisActive, not recruiting
-
Northwestern UniversityWithdrawn
-
Tulane UniversityMayne Pharma International Pty LtdTerminatedActinic KeratosesUnited States
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
University Hospital RegensburgGerman Research FoundationCompleted
-
St Vincent's University Hospital, IrelandCompleted
Clinical Trials on LAS41007
-
Almirall, S.A.CompletedActinic KeratosisGermany